| [1] |
Yokobori T, Mimori K, Ishii H, et al. Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer[J]. Ann Surg Oncol, 2010, 17(10):2601-2607.
|
| [2] |
Lin S, Guo Q, Wen J, et al. Survival analyses correlate stanniocalcin 2overexpression to poor prognosis of nasopharyngeal carcinomas[J]. J Exp Clin Cancer Res, 2014, 33:26.
|
| [3] |
Meyer HA, Tölle A, Jung M, et al. Identification of stanniocalcin 2as prognostic marker in renal cell carcinoma[J]. Eur Urol, 2009, 55(3):669-678.
|
| [4] |
Wang YY, Li L, Zhao ZS, et al. Clinical utility of measuring expression levels of KAP1, TIMP1 and STC 2 in peripheral blood of patients with gastric cancer[J]. World J Surg Oncol, 2013, 11:81.
|
| [5] |
Zhou H, Li YY, Zhang WQ, et al. Expression of stanniocalcin-1 and stanniocalcin-2 in laryngeal squamous cell carcinoma and correlations with clinical and pathological parameters[J]. PloS One, 2014, 9(4):e95466.
|
| [6] |
Kita Y, Mimori K, Iwatsuki M, et al. STC 2: a predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma[J]. Ann Surg Oncol, 2011, 18(1):261-272.
|
| [7] |
Chen X, Cheung ST, So S, et al. Gene expression patterns in human liver cancers [J]. Mol Biol Cell, 2002, 13(6):1929-1939.
|
| [8] |
Roessler S, Jia HL, Budhu A, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients[J]. Cancer Res, 2010, 70(24): 10202-10212.
|
| [9] |
Wurmbach E, Chen YB, Khitrov G, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma[J]. Hepatology, 2007, 45(4):938-947.
|
| [10] |
Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma[J]. Nat Genet, 2012, 44(6):694-698.
|
| [11] |
Mas VR, Maluf DG, Archer KJ, et al. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma[J]. Mol Med, 2009, 15(3/4):85-94.
|
| [12] |
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
|
| [13] |
Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan[J]. Hepatol Res, 2007, 37 Suppl 2:S95-100.
|
| [14] |
Zhu W, Peng Y, Wang L, et al. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy[J]. Hepatology, 2018, DOI: 10.1002/hep.29844[Epub ahead of print]. |
| [15] |
Shen XJ, Gu K, Shi JP, et al. Increased expression of stanniocalcin 2 is associated with tumor progression after radiotherapy in patients with cervical carcinoma[J]. Int J Clin Exp Pathol, 2014, 7(12):8770-8776.
|
| [16] |
Na SS, Aldonza MB, Sung HJ, et al. Stanniocalcin-2 (STC2): a potential lung cancer biomarker promotes lung cancer metastasis and progression[J]. Biochim Biophys Acta, 2015, 1854(6):668-676.
|
| [17] |
Law AY, Wong CK. Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia[J]. Exp Cell Res, 2010, 316(3):466-476.
|
| [18] |
Law AY, Wong CK. Stanniocalcin-1 and-2 promote angiogenic sprouting in HUVECs via VEGF/VEGFR 2 and angiopoietin signaling pathways[J]. Mol Cell Endocrinol, 2013, 374(1/2):73-81.
|
| [19] |
Chen B, Zeng X, He Y, et al. STC 2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways[J]. Oncotarget, 2016, 7(44):71400-71416.
|
| [20] |
Zhang ZH, Wu YG, Qin CK, et al. Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma[J]. Oncol Lett, 2014, 8(5):2160-2164.
|
| [21] |
Wang H, Wu K, Sun Y, et al. STC 2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro[J]. BMB Rep, 2012, 45(11):629-634.
|